Physician profile
Emily Nangle
NPI 1063865244
$2,251.35
in general payments reported to CMS, 2019-2025
20 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $47.92 · 2021: $46.29 · 2022: $116 · 2023: $438 · 2024: $437 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $441.05 | 2022-2025 | Tryptyr, Rocklatan, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $412.92 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $368.59 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $211.78 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $157.34 | 2023-2025 | |
| Oyster Point Pharma, INC. | $132.69 | 2023-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $129.36 | 2020-2023 | |
| Ani Pharmaceuticals, INC. | $72.84 | 2025 | Purified Cortrophin Gel |
| Glaukos Corporation | $71.93 | 2023-2024 | Idose |
| Horizon Therapeutics Plc | $45.76 | 2023 | Tepezza |
| Coopervision INC. | $41.52 | 2019 | |
| Dompe US, INC. | $38.10 | 2025 | Oxervate |
| Sight Sciences, INC. | $23.87 | 2019 | |
| Kala Pharmaceuticals, INC. | $23.67 | 2021 | |
| Astellas Pharma US INC | $21.26 | 2025 | Izervay |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $18.56 | 2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.24 | 2024 | Eylea Hd |
| Omeros Corporation | $12.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Nangle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.